Dialysis


1. Andrikos E, Tseke P, Balafa O, Pappas M, Five-year survival in comparable HD and PD patients: one center's experience, Int J Artif Organs, 2008;31:737–41.


2. Chaudhary K, Sangha H, Khanna R, Peritoneal dialysis first: rationale, Clin J Am Soc Nephrol, 2011;6:447–56.


3. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al., Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease, Arch Intern Med, 2011;171:110–8.


4. Williams JD, Craig KJ, von Ruhland C, et al., The natural course of peritoneal membrane biology during peritoneal dialysis, Kidney Int Suppl, 2003;(88):S43–9.


5. Stavenuiter AW, Farhat K, Schilte MN, et al., Bioincompatible impact of different peritoneal dialysis fluid components and therapeutic interventions as tested in a rat peritoneal dialysis model, Int J Nephrol, 2011;2011:742196.


6. ter Wee PM, van Ittersum FJ, The new peritoneal dialysis solutions: friends only, or foes in part?, Nat Clin Pract Nephrol, 2007;3:604–12.


7. Hekking LH, Zareie M, Driesprong BA, et al., Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate- buffered solution, J Am Soc Nephrol, 2001;12:2775–86.


8. Zareie M, van Lambalgen AA, ter Wee PM, et al., Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid, Perit Dial Int, 2005;25:58–67.


9. Mistry CD, Gokal R, Peers E, A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis, Kidney Int, 1994;46:496–503.


10. Posthuma N, ter Wee PM, Donker AJ, et al., Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group, Perit Dial Int, 2000;20(Suppl. 2):S106–13.


11. Posthuma N, ter Wee PM, Verbrugh HA, et al., Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance, Nephrol Dial Transplant, 1997;12:550–3.


12. Woodrow G, Oldroyd B, Stables G, et al., Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis, Nephrol Dial Transplant, 2000;15:862–6.


13. Lin A, Qian J, Li X, et al., Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid, Clin J Am Soc Nephrol, 2009;4:1799–804.


14. Finkelstein F, Healy H, Abu-Alfa A, et al., Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration, J Am Soc Nephrol, 2005;16:546–54.


15. Qi H, Xu C, Yan H, Ma J, Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials, Perit Dial Int, 2011;31:179–88.


16. Michallat AC, Dheu C, Loichot C, et al., Long daytime exchange in children on continuous cycling peritoneal dialysis: preservation of drained volume because of icodextrin use, Adv Perit Dial, 2005;21:195–9.


17. Nakamoto H, Babazono T, Kasai K, et al., Successful use of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis, Adv Perit Dial, 2005;21:168–74.


18. Ahmad M, Jeloka T, Pliakogiannis T, et al., Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis, Int Urol Nephrol, 2008;40:219–23.


19. Gokal R, Mistry CD, Peers EM, Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis, Perit Dial Int, 1995;15:226–30.


20. Adachi Y, Nakagawa Y, Nishio A, Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis, Perit Dial Int, 2006;26:405–7.


21. Davies SJ, Garcia Lopez E, Woodrow G, et al., Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange, Nephrol Dial Transplant, 2008;23:2982–8.


22. Davies SJ, Woodrow G, Donovan K, et al., Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial, J Am Soc Nephrol, 2003;14:2338–44.


23. Konings CJ, Kooman JP, Schonck M, et al., Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study, Kidney Int, 2003;63:1556–63.


24. Wolfson M, Piraino B, Hamburger RJ, Morton AR, Icodextrin Study Group, A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis, Am J Kidney Dis, 2002;40:1055–65.


25. Hiramatsu T, Furuta S, Kakuta H, Favorable changes in lipid metabolism and cardiovascular parameters after icodextrin use in peritoneal dialysis patients, Adv Perit Dial, 2007;23:58–61.


26. Davies SJ, Brown EA, Frandsen NE, et al., Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription, Kidney Int, 2005;67:1609–15.


27. Cho KH, Do JY, Park JW, Yoon KW, Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients, Nephrol Dial Transplant, 2010;25:593–9.


28. Posthuma N, ter Wee PM, Donker AJ, et al., Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell, Perit Dial Int,


52 1997;17:602–7.


29. Babazono T, Nakamoto H, Kasai K, et al., Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis, Am J Nephrol, 2007;27:409–15.


30. He Q, Zhang W, Chen J, A meta-analysis of icodextrin versus glucose containing peritoneal dialysis in metabolic management of peritoneal dialysis patients, Ren Fail, 2011;33:943–8.


31. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A, Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients, Blood Purif, 2005;23:303–10.


32. Kanbay M, Bavbek N, Delibasi T, et al., Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease, Ren Fail, 2007;29:309–13.


33. Canbakan M, Sahin GM, Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients, Ren Fail, 2007;29:289–93.


34. Gürsu EM, Ozdemir A, Yalinbas B, et al., The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients, Clin Nephrol, 2006;66:263–8.


35. Paniagua R, Ventura MD, Avila-Díaz M, et al., Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients, Perit Dial Int, 2009;29:422–32.


36. Adachi Y, Nakagawa Y, Nishio A, In patients treated with peritoneal dialysis, icodextrin improves erythropoietin- resistant anemia through blockade of asialo receptors on hepatocytes, Adv Perit Dial, 2006;22:41–4.


37. García-López E, Anderstam B, Heimbürger O, et al., Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients, Perit Dial Int, 2005;25:181–91.


38. Konings CJ, Schalkwijk CG, van der Sande FM, et al., Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)- (carboxyethyl)lysine, Perit Dial Int, 2005;25:591–5.


39. Kooman JP, Schalkwijk CG, Konings CJ, The increase in plasma levels of Nepsilon-(carboxymethyl)lysine during icodextrin treatment of peritoneal dialysis patients is not associated with increased plasma levels of vascular cell adhesion molecule-1, Perit Dial Int, 2006;26:410–1.


40. Lin W, Chen YC, Wu MS, et al., Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients, Ren Fail, 2009;31:98–105.


41. Moriishi M, Kawanishi H, Icodextrin and intraperitoneal inflammation, Perit Dial Int, 2008;28(Suppl. 3):S96–S100.


42. Moriishi M, Kawanishi H, Watanabe H, Tsuchiya S, Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane, Adv Perit Dial, 2005;21:21–4.


43. Korte MR, Sampimon DE, Lingsma HF, et al., Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study, Perit Dial Int, 2011;31:269–78.


44. Kuriyama R, Tranaeus A, Ikegami T, Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients, Adv Perit Dial, 2006;22:108–10.


45. Han SH, Ahn SV, Yun JY, et al., Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis, Nephrol Dial Transplant, 2011 Oct 3. [Epub ahead of print]


46. Takatori Y, Akagi S, Sugiyama H, et al., Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial, Clin J Am Soc Nephrol, 2011;6:1337–44.


47. Mortier S, Faict D, Schalkwijk CG, et al., Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane, Kidney Int, 2004;66:1257–65.


48. Goodship TH, Lloyd S, McKenzie PW, et al., Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis, Clin Sci (Lond), 1987;73:471–8.


49. Park MS, Heimbürger O, Bergström J, et al., Peritoneal transport during dialysis with amino acid-based solutions, Perit Dial Int, 1993;13:280–8.


50. Faller B, Aparicio M, Faict D, et al., Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis, Nephrol Dial Transplant, 1995;10:1432–7.


51. Gonzalez AO, Melon CP, Esteban J, et al., Intraperitoneal amino acids in CAPD: an 18 month experience, Perit Dial Int, 1999;19:494–6.


52. Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A, Szajdak L, Effects of amino acid dialysis solution on the nutrition of continuous ambulatory peritoneal dialysis patients, Perit Dial Int, 1999;19:462–70.


53. Jones MR, Gehr TW, Burkart JM, et al., Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution, Perit Dial Int, 1998;18:210–6.


54. Asola M, Virtanen K, Någren K, et al., Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle, Kidney Int Suppl, 2008;(108):S131–6.


55. Jones M, Hagen T, Boyle CA, et al., Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study, Am J Kidney Dis, 1998;32:761–9.


56. Misra M, Ashworth J, Reaveley DA, et al., Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients, Adv Perit Dial, 1996;12:311–4.


57. Li FK, Chan LY, Woo JC, et al., A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD, Am J Kidney Dis, 2003;42:173–83.


58. Maurer O, Saxenhofer H, Jaeger P, et al., Six-month overnight administration of intraperitoneal amino acids does not


improve lean mass, Clin Nephrol, 1996;45:303–9.


59. Qamar IU, Secker D, Levin L, et al., Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis, Perit Dial Int, 1999;19:237–47.


60. Taylor GS, Patel V, Spencer S, et al., Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients, Clin Nephrol, 2002;58:445–50.


61. Tjiong HL, van den Berg JW, Wattimena JL, et al., Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis, J Am Soc Nephrol, 2005;16:1486–93.


62. Canepa A, Carrea A, Menoni S, et al., Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids, Kidney Int, 2001;59:1967–73.


63. Vychytil A, Födinger M, Pleiner J, et al., Acute effect of amino acid peritoneal dialysis solution on vascular function, Am J Clin Nutr, 2003;78:1039–45.


64. Dervisoglu E, Ozdemir O, Yilmaz A, Commencing peritoneal dialysis with 1.1% amino acid solution does not influence biochemical nutritional parameters in incident CAPD patients, Ren Fail, 2010;32:653–8.


65. Dousdampanis P, Trigka K, Chu M, et al., Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature, Int Urol Nephrol, 2011;43:203–9.


66. Sav T, Oymak O, Inanc MT, et al., Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis, Perit Dial Int, 2009;29:443–9.


67. Kopple JD, Bernard D, Messana J, et al., Treatment of malnourished CAPD patients with an amino acid based dialysate, Kidney Int, 1995;47:1148–57.


68. McCormick BB, Mujais S, Poirier F, et al., Metabolic effects of incremental doses of intraperitoneal amino acids on automated peritoneal dialysis, Perit Dial Int, 2010;30:201–7.


69. Le Poole CY, van Ittersum FJ, Weijmer MC, et al., Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study, Adv Perit Dial, 2004;20:170–6.


70. Schalkwijk CG, Posthuma N, ten Brink HJ, et al., Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids, Perit Dial Int, 1999;19:325–33.


71. Le Poole CY, van Ittersum FJ, Valentijn RM, et al., "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO, Perit Dial Int, 2012;32:45–54.


72. Le Poole CY, Welten AG, Weijmer MC, et al., Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious, Perit Dial Int, 2005;25(Suppl. 3):S64–8.


73. Le Poole CY, Welten AA, ter Wee PM, et al., A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation, Perit Dial Int, 2011 Nov 1. [Epub ahead of print]


74. Baxter Healthcare Corporation, IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (Impendia) (NCT00567398). Available at: http://clinicaltrials.gov/ct2/show/NCT00567398 (accessed February 24, 2012).


75. Kawanishi H, McIntyre C, Complementary use of peritoneal and hemodialysis: therapeutic synergies in the treatment of end- stage renal failure patients, Kidney Int Suppl, 2008;(108):S63–7.


76. McIntyre CW, Bimodal dialysis: an integrated approach to renal replacement therapy, Perit Dial Int, 2004;24:547–53.


77. Kawanishi H, Hashimoto Y, Nakamoto H, et al., Combination therapy with peritoneal dialysis and hemodialysis, Perit Dial Int, 2006;26:150–4.


78. Kawanishi H, Moriishi M, Clinical effects of combined therapy with peritoneal dialysis and hemodialysis, Perit Dial Int, 2007;27(Suppl. 2):S126–9.


79. Zareie M, Keuning ED, ter Wee PM, et al., Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats, Nephrol Dial Transplant, 2005;20:189–93.


80. Choi HY, Kim DK, Lee TH, et al., The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial, Perit Dial Int, 2008;28:174–82.


81. Kim SG, Kim S, Hwang YH, et al., Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study), Perit Dial Int, 2008;28(Suppl. 3):S117–22.


82. Han SH, Ahn SV, Yun JY, et al., Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions, Am J Kidney Dis, 2009;54:711–20.


83. Lee HY, Choi HY, Park HC, et al., Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome, Nephrol Dial Transplant, 2006;21:2893–9.


84. Lee HY, Park HC, Seo BJ, et al., Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance), Perit Dial Int, 2005;25:248–55.


85. Srivastava S, Hildebrand S, Fan SL, Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival, Kidney Int, 2011;80:986–91.


EUROPEAN NEPHROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76